Quick answer
Dr. Hannah O'Connor is a Advanced Therapies Columnist for Europe & United Kingdom pharmaceutical intelligence editor on NovaPharmaNews, with 24 published articles covering EMA regulatory actions, clinical development, and market-moving news. Dr. Hannah O'Connor writes on advanced therapy medicinal products, translational milestones, and EU regulatory expectations. Across 13 years in translational medicine, she has advised teams on target validation and evidence packages for high-impact programs.
About Dr. Hannah O'Connor
Dr. Hannah O'Connor writes on advanced therapy medicinal products, translational milestones, and EU regulatory expectations. Across 13 years in translational medicine, she has advised teams on target validation and evidence packages for high-impact programs.
Coverage focus
Topics and beats Dr. covers across Europe & United Kingdom.
Explore related intelligence
Entity directories linked from this author's coverage.
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways
Articles by Dr. Hannah O'Connor
Oncolytics Biotech Reports Durable Responses with Pelareorep in RAS-Mutant Colorectal Cancer Trial
Oncolytics Biotech announces sustained clinical benefit with pelareorep immunotherapy in patients with RAS-mutant, microsatellite-stable colorectal cancer.
FDA Approves Auvelity: A New Option for MDD
The FDA has approved Auvelity, a new oral antidepressant combining bupropion and dextromethorphan, for the treatment of major depressive disorder (MDD) in adults. Manufactured by Axsome Therapeutics, this approval marks a significant advancement in MDD treatment options.
Auvelity FDA Approval: New MDD Treatment Option
The FDA has approved Auvelity, a new oral treatment for major depressive disorder (MDD) in adults, marking a significant advancement in mental health therapeutics. Manufactured by Axsome Therapeutics, this approval offers a novel option for patients seeking relief from MDD.
Moderna FDA Talks Focus on Phase 4 COVID Vaccine Data
Moderna is currently in discussions with the U.S. Food and Drug Administration (FDA) regarding the submission of Phase 4 data for its COVID-19 vaccine, mRNA-1273. These talks are crucial for understanding the vaccine's ongoing real-world effectiveness and post-marketing surveillance.
Osimertinib FDA Approval Expands Early-Stage NSCLC Treatment
The FDA has approved osimertinib (Tagrisso) for adjuvant treatment of early-stage NSCLC, marking a milestone for AstraZeneca and expanding treatment options. Learn about the clinical data, market impact, and investment implications.
Telix Pharmaceuticals' TLX101-Px (Pixlumi) Brain Cancer Imaging Drug Accepted for European Review
Telix Pharmaceuticals' TLX101-Px (Pixlumi) glioma imaging drug enters 210-day European regulatory review after MAA acceptance, targeting brain cancer diagnosis.
European Commission Approves POHERDY, First Pertuzumab Biosimilar in Europe by Henlius and Organon
EC grants marketing authorization for POHERDY (pertuzumab), the first approved biosimilar to PERJETA in Europe, developed by Henlius Biotech and Organon.
Norgine Receives European Commission Approval for XOLREMDI (Mavorixafor) as First WHIM Syndrome Treatment
Norgine's XOLREMDI becomes first authorized treatment for WHIM syndrome in Europe, marking breakthrough for ultra-rare immunodeficiency patients.
EMA Establishes Expert Panel to Strengthen COVID-19 mRNA Vaccine Trust Including Spikevax and Comirnaty
European Medicines Agency forms international expert panel to enhance public confidence in COVID-19 mRNA vaccines including Spikevax and Comirnaty.
Biosimilars in Japan: Market Growth and PMDA Regulatory Insights 2024
This article delves into the expanding biosimilars market in Japan, focusing on trastuzumab's role in cancer treatment and the latest PMDA regulatory updates for 2024.
COFEPRIS Biosimilars Regulation: What You Need to Know in 2024
Learn about COFEPRIS's updated biosimilars regulations in 2024, focusing on safety, efficacy, and the impact on drugs like trastuzumab for breast cancer.
SFDA Accelerated Approval Oncology: Impact on Innovative Drugs in Saudi Arabia
The SFDA's Accelerated Approval program significantly impacts the availability of innovative oncology drugs, such as Keytruda, for cancer patients in Saudi Arabia.
Solid Biosciences Receives European Orphan Drug Designation for SGT-003 Duchenne Muscular Dystrophy Treatment
Solid Biosciences secures European Commission orphan drug designation for SGT-003, advancing gene therapy development for Duchenne muscular dystrophy patients.
Mundipharma's REZZAYO (Rezafungin) Meets Primary Endpoint in Phase III ReSPECT Trial for Fungal Disease Prevention
Mundipharma announces positive Phase III ReSPECT trial results for REZZAYO (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients.
GLP-1 Eating Disorder Risk: What You Need to Know
Recent concerns about GLP-1 receptor agonists like semaglutide highlight potential eating disorder risks. This article reviews current evidence, FDA stance, and safety considerations.
EMA CHMP Recommends Five New Medicines Including Tolebrutinib (Cenrifki) for Approval in April 2026
European Medicines Agency's CHMP committee recommended five new medicines for approval in April 2026, including tolebrutinib (Cenrifki) for multiple sclerosis treatment.
COFEPRIS Drug Approvals: Trends and Market Impact in Oncology 2025
This article analyzes COFEPRIS drug approvals in oncology, highlighting trends and market impacts for drugs like Pembrolizumab by 2025.
Pembrolizumab Expanded Label: KEYNOTE-826 Trial Transforms Advanced Cervical Cancer Care
The KEYNOTE-826 trial has led to pembrolizumab's expanded label, marking a significant advancement in the treatment of advanced cervical cancer.
Genomics Services Market to Reach $24 Billion by 2033 as Precision Medicine Adoption Accelerates
The global genomics services market is projected to grow at 11.2% CAGR through 2033, driven by precision medicine advances and digital health initiatives.
FDA Approval ResVax: Comprehensive Market Analysis of Novel mRNA RSV Vaccine
This article provides a comprehensive market analysis of ResVax, the newly FDA-approved mRNA vaccine targeting respiratory syncytial virus (RSV).
Tilray Brands Positioned for Major U.S. Medical Cannabis Expansion Following Historic Rescheduling
Tilray Brands leverages international medical cannabis expertise across 20+ countries to capitalize on U.S. market expansion opportunities amid cannabis rescheduling.
Phase 1 Trial Evolution: EMA’s New Safety Monitoring Requirements Explained
This article delves into the EMA's updated safety monitoring requirements for Phase 1 trials, focusing on DrugX's role in cancer treatment and patient safety.
Pharmaceutical Intermediates Market to Reach $57 Billion by 2035 as Generic Drug Manufacturing Drives 4.5% Annual Growth
Global pharmaceutical intermediates market projected to grow from $36.62B to $57.03B by 2035, driven by generic drug demand and advanced manufacturing.
Pembrolizumab Plus Lenvatinib Shows Promise for Rare Clear Cell Gynecological Cancers in Phase 2 Trial
LARA Phase 2 trial published in The Lancet Oncology demonstrates promising clinical activity of pembrolizumab plus lenvatinib for recurrent clear cell cancers.
Frequently asked questions
Who writes NovaPharmaNews articles?
Each story is attributed to a named editor or analyst with a public author profile. Profiles list credentials, coverage focus, and every published article so readers and AI systems can verify expertise and trace claims to a accountable journalist.
How do I find more coverage from this author?
Scroll to the article archive on this page, or use the topic chips linked from the author’s specializations. The regional authors directory lists every active contributor in this edition.
How does author coverage connect to companies and pipeline data?
Articles link to company profiles, drug INN pages, clinical trials, and pipeline programs when entities are tagged. Use the intelligence spokes on each story or browse topic hubs from the author’s beat.